**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A 7-carboxymethyloxy-3',4',5-trimethoxy flavone monohydrate ~~flavone.monohydrate~~ represented by formula 1 having mucus protecting activity for gastrointestinal tract including colon[[.]]

<Formula 1>




2. (Currently Amended) A 7-carboxymethyloxy-3',4',5-trimethoxy flavone solvate ~~flavone.solvate~~ represented by formula 1a[[.]]

<Formula 1a>




3. (Currently Amended) The 7-carboxymethyloxy-3',4',5-trimethoxy flavone solvate ~~flavone.solvate~~ as set forth in claim 2, wherein the solvent is anhydrous ethanol.

4. (Currently Amended) A preparation method of 7-carboxymethyloxy-3',4',5-trimethoxy flavone represented in scheme 3, comprising the following steps:

(1) reacting a ~~A~~ compound of formula 3 ~~is reacted~~ with a methylating reagent ~~agent~~ in the presence of base to convert a hydroxyl group of carbon-3' into a methoxy group, followed by acid treatment to prepare a compound of formula 4 (Step 1);

(2) reacting the ~~The~~ compound of formula 4 ~~is reacted~~ in the presence of base with alpha-haloacetate to provide ~~in which carboxyl group is protected to give~~ a compound of formula 5 containing a protected carboxyl group (Step 2);

(3) reacting the ~~The~~ compound of formula 5 ~~is reacted~~ with a methylating agent ~~reagent~~ to convert a hydroxyl group of carbon-5 into a methoxyl group, resulting in a compound of formula 6 (Step 3); and

(4) deprotecting ~~Deprotection of~~ the compound of formula 6 ~~is performed~~, resulting in 7-carboxymethyloxy-3',4',5-trimethoxy flavone of formula 2 (Step 4)[[.]]

<Scheme 3>




~~(Wherein,~~ wherein R' is a protecting group selected from ~~a~~ the group consisting of ethyl, methyl, t-butyl, benzyl, trichloroethyl and silyl. ~~silyl)~~

5. (Currently Amended) The preparation method as set forth in claim 4, wherein ~~the~~ a reaction solvent used in step 1 is selected from ~~a~~ the group consisting of dimethylformamide, dimethylsulfoxide and acetone, the base of step 1 is selected from ~~a~~ the group consisting of

potassium carbonate, sodium hydroxide, potassium hydroxide and sodium carbonate, the methylating ~~agent~~ reagent of step 1 is selected from ~~a~~ the group consisting of methyl iodide ($CH_3I$) and dimethyl sulfate ($(CH_3)_2SO_4$), and the acid of step 1 is selected from ~~a~~ the group consisting of hydrochloric acid and sulfuric acid.

6. (Currently Amended) The preparation method as set forth in claim 4, wherein ~~the~~ a reaction temperature is 0 °C ~ 150 °C.

7. (Currently Amended) The preparation method as set forth in claim 6, wherein ~~the~~ a reaction temperature is 0 °C ~ 90 °C.

8. (Currently Amended) The preparation method as set forth in claim 4, wherein the base used in step 2 is selected from ~~a~~ the group consisting of inorganic bases, ~~base such as potassium carbonate, sodium hydroxide, potassium hydroxide and sodium carbonate;~~ alcoholic metal salts, ~~salt such as sodium methoxide and sodium ethoxide;~~ alkaline metal hydrides ~~hydride such as sodium hydride;~~ and alkaline earth metal hydrides ~~hydride such as calcium hydride~~.

9. (Currently Amended) A preparation method of 7-carboxymethyloxy-3',4',5-trimethoxy flavone monohydrate ~~flavone.monohydrate~~ represented by formula 1 of claim 1, comprising: ~~which is characterized by the process of~~

stirring the compound of formula 2 obtained from ~~the~~ step 4 of claim 4 in a medium containing water as shown in ~~the below~~ scheme 4[[.]]

<Scheme 4>




10. (Currently Amended) The preparation method of 7-carboxymethyloxy-3',4',5-trimethoxy flavone monohydrate ~~flavone.monohydrate~~ of claim 1 as set forth in claim 9, wherein the medium containing water is ethanol or acetone.

11. (Currently Amended) A preparation method of 7-carboxymethyloxy-3',4',5-trimethoxy flavone monohydrate ~~flavone.monohydrate~~ represented by formula 1 of claim 1, comprising:

placing ~~in which~~ the compound of formula 2 obtained from the step 4 of claim 4 ~~was placed~~ under humidified atmosphere as shown in ~~the below~~ scheme 5[[.]]

<Scheme 5>




12. (Currently Amended) A preparation method of 7-carboxymethyloxy-3',4',5-trimethoxy flavone monohydrate ~~flavone.monohydrate~~ represented by formula 1 of claim 1, comprising: ~~which includes the steps of~~

stirring the compound of formula 2 obtained from ~~the~~ step 4 of claim 4 ~~scheme 3~~ in an anhydrous alcohol to give 7-carboxymethyloxy-3',4',5-trimethoxy flavone solvate ~~flavone.solvate~~ represented by formula 1a; and

placing ~~leaving the solvate~~ the compound of formula 1a under humidified atmosphere as shown in ~~the below~~ scheme 6[[.]]

<Scheme 6>



13. (Currently Amended) The preparation method of 7-carboxymethyloxy-3',4',5-trimethoxy flavone monohydrate ~~flavone.monohydrate~~ of claim 1 as set forth in claim 12, wherein the anhydrous alcohol is anhydrous ethanol.

14. (Currently Amended) A pharmaceutical composition ~~for the protection of gastrointestinal tract including the colon and the treatment of gastrointestinal diseases containing the~~ comprising 7-carboxymethyloxy-3',4',5-trimethoxy flavone monohydrate ~~flavone.monohydrate~~ of claim 1 as an effective ingredient.

15. (Currently Amended) A pharmaceutical composition for the protection of the gastrointestinal tract including ~~the~~ colon and the treatment of gastrointestinal diseases ~~such as gastritis, gastric ulcer, ulcerative colitis and Crohn's disease containing the~~ comprising 7-carboxymethyloxy-3',4',5-trimethoxy flavone monohydrate ~~flavone.monohydrate~~ of claim 1 as an effective ingredient.

16. (New) The preparation method as set forth in claim 8, wherein the base used in step 2 is selected from the group consisting of potassium carbonate, sodium hydroxide, potassium hydroxide, sodium carbonate, sodium methoxide, sodium ethoxide, sodium hydride and calcium hydride.

17. (New) The pharmaceutical composition of claim 15, wherein the gastrointestinal diseases are selected from the group consisting of gastritis, gastric ulcer, ulcerative colitis and Crohn's disease.